• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

多发性骨髓瘤合并第二原发恶性肿瘤。

Multiple myeloma in association with second malignancy.

作者信息

Grudeva-Popova J, Nenova I, Spasova M, Yaneva M, Beleva E, Ananoshtev N

机构信息

Department of Oncology and Hematology, University Multiprofile Hospital for Active Treatment "Sv. Georgi", Plovdiv, Bulgaria.

出版信息

J BUON. 2013 Apr-Jun;18(2):448-52.

PMID:23818360
Abstract

PURPOSE

To look at the frequency of second primary malignancies (SECMAL) in patients with multiple myeloma (MM).

METHODS

The medical files of 332 patients with MM (whole group), diagnosed and treated at the University Multiprofile Hospital for Active Treatment "Sv. Georgi" and the Comprehensive Oncology Hospital (Plovdiv) for a 20-year period (1990-2010) were retrospectively analyzed. MM patients with SECMAL constituted the study group. A control group comprised patients with solid tumors associated with SECMAL. This group derived from a sample of 21768 patients with solid tumors.

RESULTS

In the study group, SECMAL was diagnosed in 4.52% (N=15) of the patients, while in the control group this figure was 5.09% (N=1108) (p>0.05). The diagnosis of MM preceded the occurrence of SECMAL in 35.71% of the study group patients, the median interval being 6.6 years (range 5-14). More frequently the diagnosis of the solid tumor preceded the occurrence of MM (66.67%). Breast cancer and gastric cancer were encountered with the highest frequency (26.67% each). The median survival (77.2 months, range 44-129) was significantly longer in the group with MM and SECMAL compared to the whole group with MM (median 38.6 months, range 10-58; p<0.05).

CONCLUSION

The rate of MM with other malignant diseases is comparable with the frequency of SECMAL in other lymphoproliferative disorders and solid tumors. The occurrence of SECMAL during the clinical course of MM is not a frequent event and is expected in the rare cases with longer survival.

摘要

目的

研究多发性骨髓瘤(MM)患者中第二原发性恶性肿瘤(SECMAL)的发生率。

方法

回顾性分析在“圣乔治”大学综合积极治疗医院和普罗夫迪夫综合肿瘤医院诊断并治疗的332例MM患者(全组)20年期间(1990 - 2010年)的病历。患有SECMAL的MM患者构成研究组。对照组包括与SECMAL相关的实体瘤患者。该组来自21768例实体瘤患者的样本。

结果

在研究组中,4.52%(N = 15)的患者被诊断为SECMAL,而在对照组中这一数字为5.09%(N = 1108)(p>0.05)。在研究组35.71%的患者中,MM的诊断先于SECMAL的发生,中位间隔时间为6.6年(范围5 - 14年)。实体瘤的诊断更常先于MM的发生(66.67%)。乳腺癌和胃癌的发生率最高(各为26.67%)。与整个MM组(中位生存期38.6个月,范围10 - 58个月;p<0.05)相比,伴有SECMAL的MM组中位生存期显著更长(77.2个月,范围44 - 129个月)。

结论

MM合并其他恶性疾病的发生率与其他淋巴增生性疾病和实体瘤中SECMAL的发生率相当。MM临床过程中SECMAL的发生并不常见,预计仅在少数生存期较长的病例中出现。

相似文献

1
Multiple myeloma in association with second malignancy.多发性骨髓瘤合并第二原发恶性肿瘤。
J BUON. 2013 Apr-Jun;18(2):448-52.
2
Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma.硼替佐米-美法仑-泼尼松与美法仑-泼尼松治疗既往未经治疗的多发性骨髓瘤患者的持续总生存获益和不增加第二恶性肿瘤风险。
J Clin Oncol. 2013 Feb 1;31(4):448-55. doi: 10.1200/JCO.2012.41.6180. Epub 2012 Dec 10.
3
[Association of multiple myeloma and solid neoplasms: analysis of 13 cases].[多发性骨髓瘤与实体肿瘤的关联:13例病例分析]
Rev Clin Esp. 1999 Nov;199(11):725-8.
4
Multiple myeloma and other malignancies: a pilot study from the Houston VA.多发性骨髓瘤及其他恶性肿瘤:来自休斯顿退伍军人事务部的一项初步研究。
Clin Lymphoma Myeloma Leuk. 2014 Apr;14(2):102-6. doi: 10.1016/j.clml.2013.10.006. Epub 2013 Nov 15.
5
[Clinical features and prognosis of multiple primary tumors of lung combined with other organs--report of 281 cases].[肺多原发性肿瘤合并其他器官的临床特征及预后——附281例报告]
Ai Zheng. 2006 Jun;25(6):731-5.
6
Secondary or concomitant neoplasms among adults diagnosed with acute lymphoblastic leukemia and treated according to the LALA-87 and LALA-94 trials.在根据LALA - 87和LALA - 94试验进行治疗的成年急性淋巴细胞白血病患者中出现的继发性或伴发性肿瘤。
Cancer. 2007 Dec 15;110(12):2747-55. doi: 10.1002/cncr.23097.
7
Continuous lenalidomide treatment for newly diagnosed multiple myeloma.来那度胺持续治疗新诊断的多发性骨髓瘤。
N Engl J Med. 2012 May 10;366(19):1759-69. doi: 10.1056/NEJMoa1112704.
8
Multiple myeloma and its therapies: to what extent do they contribute to the increased incidence of second malignant neoplasms?多发性骨髓瘤及其治疗:在多大程度上导致第二恶性肿瘤发病率的增加?
Curr Med Res Opin. 2012 Jul;28(7):1129-40. doi: 10.1185/03007995.2012.688800. Epub 2012 Jun 6.
9
[Multiple neoplasms in gastric cancer patients: patterns of development, results of treatment].[胃癌患者的多种肿瘤:发生模式及治疗结果]
Vopr Onkol. 2012;58(6):754-61.
10
Non-Hodgkin lymphomas and carrier state of viral hepatitis B and C.
J BUON. 2013 Jan-Mar;18(1):239-44.

引用本文的文献

1
The risk and survival of multiple myeloma as the second primary malignancy in a single Chinese center.中国某单一中心多发性骨髓瘤作为第二原发性恶性肿瘤的风险与生存情况
Transl Cancer Res. 2024 Jun 30;13(6):2905-2912. doi: 10.21037/tcr-23-2336. Epub 2024 Jun 11.
2
Gastric Cancer or Plasmacytoma in a Seemingly Well-Controlled Multiple Myeloma Patient?一名看似病情得到良好控制的多发性骨髓瘤患者,却患上了胃癌或浆细胞瘤?
Turk J Haematol. 2021 Jun 1;38(2):169-170. doi: 10.4274/tjh.galenos.2021.2020.0645. Epub 2021 Feb 9.
3
Concomitant multiple myeloma, gastric adenocarcinoma and Evan's syndrome in a patient presenting with anaemia.
一名贫血患者同时患有多发性骨髓瘤、胃腺癌和伊文氏综合征。
BMJ Case Rep. 2016 Dec 15;2016:bcr2016217697. doi: 10.1136/bcr-2016-217697.